Syndax raises $6 million to support ENCORE 301 study in breast cancer
August 18, 2015
Dr. David Matthews has joined the company as the Vice President of Drug Discovery and Exploratory Development. Dr. Matthews was previously at Exelixis for 10 years, most recently as the Executive Director, Oncology Discovery, where he was responsible for establishing scientific guidance and ongoing strategic planning for oncology drug discovery. His work there contributed to the discovery and clinical advancement of ten oncology development candidates, including direct experience with PI3K and mTOR inhibitors. "We are delighted with the appointment of Dr. Matthews, who has a terrific oncology small molecule drug discovery and development experience that will be valuable as we advance our programs," said Dr. Julie Cherrington, Pathway's CEO.
Dr. Marie O'Farrell has also recently joined Pathway Therapeutics as the Executive Director of Translational Medicine. Dr. O'Farrell has a 13 year history in the biotechnology industry, with wide therapeutic area experience including oncology, diabetes, virology, stem cells, and inflammation; as well as broad functional expertise across preclinical and clinical development, regulatory and project management. Importantly, Dr. O'Farrell established pioneering translational medicine approaches at SUGEN which accelerated the clinical development and ultimate regulatory approval of SUTENT.
SOURCE Pathway Therapeutics